All articles tagged with #varda space industries
A commercial Varda Space Industries W-1 capsule reentered Earth's atmosphere at Mach 25 and landed at the Utah Test and Training Range after a mission to produce ritonavir crystals for pharmaceutical processing, a first for a commercial spacecraft under FAA Part 450 licensing; the mission included capsule separation from its satellite and onboard footage of the dramatic reentry.
Varda Space Industries is launching its first in-house built spacecraft, W-4, on a SpaceX rideshare mission, featuring a fully domestically produced heat shield and a new spacecraft bus design to enable high-frequency reentries and microgravity manufacturing experiments, supported by a five-year FAA reentry license for unlimited landings in Australia, as part of its plan to expand space-based pharmaceutical and research operations.
The Federal Aviation Administration (FAA) is updating its licensing regulations to require spacecraft designed to reenter to have a reentry license before launch, following an incident where Varda Space Industries launched a spacecraft without the necessary approvals to return. The FAA's decision is aimed at ensuring safety and preventing uncontrolled reentries, with the agency planning to clarify its policies around reentry and licensing requirements as commercial spacecraft reentries become more common.
Varda Space Industries secures $90 million in Series B funding following the successful return of its first drug manufacturing capsule from orbit, marking a significant milestone for the company. The startup, founded by Delian Asparouhov and Will Bruey, aims to commercialize microgravity research for pharmaceutical crystallization, leveraging low-cost rideshare launches and innovations in satellite bus manufacturing. With a focus on pharmaceuticals, Varda plans to scale its missions, drive down mission costs, and improve processing capabilities for on-board pharmaceutical reactors, with a handful of contracts already in place and the next manufacturing mission set to launch later this year.
Varda Space Industries has raised $90 million in a Series B round to scale up production of systems for manufacturing pharmaceuticals in orbit and returning them to Earth. The funding follows the successful conclusion of its first demonstration mission, W-1, which landed a capsule in Utah on Feb. 21, showcasing the ability to produce pharmaceuticals in microgravity. The company plans to use the funding to increase its flight rate and serve commercial biopharmaceutical customers, with a next mission scheduled to launch this summer using its own capsule and a spacecraft bus built by Rocket Lab.
Varda Space Industries successfully returned its W-1 capsule from space, carrying the HIV/AIDS medication ritonavir, which was processed in microgravity. The mission aimed to test the feasibility of manufacturing pharmaceuticals in space, with the space-processed ritonavir surviving reentry and providing crucial data on the effects of spaceflight on pharmaceutical production. Varda Space hopes to inspire the viability of space-processed pharmaceuticals and enable cost-effective access to next-generation therapeutics.
Varda Space Industries successfully demonstrated the potential for automated pharmaceutical drug manufacturing in space with the recent landing of a space capsule carrying a small batch of Ritonavir, an antiviral drug. Microgravity conditions in space have been found to improve the crystallization process, potentially leading to the creation of more effective medicines. While the economic challenges of manufacturing in space remain, Varda plans to make their spacecraft more versatile and reusable, paving the way for new applications of microgravity in drug development and other life sciences.
Varda Space Industries releases stunning footage of its W-1 capsule hurtling toward Earth at speeds of greater than Mach 25, showcasing the forces of Earth’s atmosphere and the spacecraft's special heat shield. The uncrewed capsule, which landed at the Utah Test and Training Range, carried crystals of an antiviral drug cultivated in space as part of Varda's efforts to become a leader in off-Earth manufacturing. The company highlights the unique benefits of processing materials in microgravity. NASA also successfully brought back a capsule containing samples gathered from an asteroid, marking a first for the space agency.
Varda Space Industries released incredible first-person footage of its W-1 space capsule's return trip to Earth, from separation in orbit to fiery reentry and landing at the Utah Test and Training Range. The capsule, which spent eight months in low Earth orbit, is part of Varda's efforts to develop mini-labs for pharmaceutical production in space, specifically for the HIV drug ritonavir. The capsule was attached to Rocket Lab's Photon satellite "bus," which provided power, communications, and altitude control before burning up in Earth's atmosphere. The ritonavir crystals grown in orbit will now be analyzed by Improved Pharma.
Varda Space Industries shares stunning footage of its space capsule reentering Earth's atmosphere at 25 times the speed of sound after an eight-month-long mission to grow crystals of an antiviral drug in microgravity, overcoming regulatory hurdles for its return. The video showcases the capsule peacefully floating in space, heating up with magenta hues giving way to orange and red, and finally dipping into lush cloud cover, resembling a scene from a sci-fi film.
Varda Space Industries' W-1 spacecraft successfully landed back on Earth after months in space, capturing unedited footage of its descent through Earth's atmosphere. The capsule, a test for drug production in microgravity, produced crystals of the antiretroviral drug Ritonavir. Its time in space was spent on the Rocket Lab Photon spacecraft, and the successful mission demonstrated in-space manufacturing. The capsule and pharmaceutical sample have been transported back for analysis, with flight data to be shared with NASA and the U.S. Air Force.
Varda Space Industries' W-1 spacecraft captured footage of its reentry into Earth's atmosphere at 25 times the speed of sound, showcasing the intense journey from space to a remote area in Utah. The capsule, designed to withstand atmospheric heating, conducted experiments in microgravity, including the production of an HIV drug, before returning to Earth. This event highlights the increasing involvement of commercial companies in space exploration and the unique opportunities for processing materials in microgravity.
Varda Space Industries' W-1 spacecraft successfully landed at the Utah Test and Training Range, capturing stunning reentry footage from separation in low Earth orbit to parachute deploy. The capsule, part of a Rocket Lab Photon spacecraft, was used to test in-space manufacturing technologies, producing ritonavir, an antiviral drug, in microgravity. Varda aims to make LEO more accessible to commercial industries and plans to share reentry data with NASA and the Air Force.
Varda Space Industries successfully obtained FAA approval for the reentry of its space capsule, marking the first commercial spacecraft landing at a military test range. The company's achievement was the result of navigating complex regulatory and bureaucratic processes, including securing a commercial reentry license and coordinating with government entities. The spacecraft landed in the Utah desert and was retrieved for transport back to Varda's headquarters, signaling a significant milestone for the in-space manufacturing company.
Varda Space Industries' W-1 mission capsule, carrying antiviral drugs grown in microgravity, has returned to Earth from Low Earth Orbit. The company aims to develop pharmaceuticals and other products in space and return them to Earth via their proprietary reentry capsules, taking advantage of the declining cost of sending payloads to space. The drugs will undergo post-mission analysis, and the company is preparing for its second launch this summer, continuing its efforts in space manufacturing and microgravity research.